Check for updates

scientific data

Monitoring measles infections OPENDATA DESCRIPTOR USING flight passenger dynamics in Europe: A data-driven approach

Chiara Romano¹ ✉**, Francesco Branda [1](http://orcid.org/0000-0002-9485-3877)** ✉**, Fabio Scarpa2, Giovanna Jona Lasinio³ & Massimo Ciccozzi**¹

This paper presents an open-access repository collecting information on measles virus infections and fight passenger movements in European countries from 2011 to 2023. It provides a comprehensive overview of reported measles cases and measles-mumps-rubella (MMR) vaccination coverage from authoritative organizations such as the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC). In addition, the dataset includes detailed data on passenger movements between countries, facilitating analysis of cross-border disease transmission. This resource enables more precise spatial analyses for monitoring and forecasting measles outbreaks, underscoring the importance of adequate vaccination coverage and sustained international surveillance to prevent the spread of the disease.

Background & Summary

Measles, caused by *Morbillivirus*, a member of the Paramyxoviridae family, represents one of the most contagious viral diseases known to humans. Measles virus (MV) has a negative-sense single-stranded RNA genome and is mainly transmitted by airborne route through respiratory droplets or direct contact with infected secre-tions^{[1](#page-6-0)}. MV has an incubation period of about 10-12 days, during which the patient is asymptomatic but already contagious^{[2](#page-6-1)}. The disease begins with general symptoms such as high fever, cough, rhinitis, and conjunctivitis. Afer a few days, the typical rash appears, consisting of red macules extending from the face to the rest of the body. One of the distinctive clinical signs is the appearance of Koplik's spots, small whitish lesions inside the mouth³. Measles is highly contagious: it is estimated that an infected person can transmit the virus to about 90% of nonimmune persons with whom he or she comes in contact^{[4](#page-6-3)}. This contagiousness is compounded by the ability of the virus to remain active in the air or on surfaces for several hours, thus increasing the likelihood of transmission^{[5](#page-6-4)}. Measles can have serious complications, especially in malnourished children and people with compromised immune systems. Common complications include encephalitis, which can lead to permanent brain damage, pneumonia, and blindness^{[6](#page-6-5)}. In developing countries, where malnutrition and limited access to health services are prevalent, the mortality rate associated with measles can be as high as 10–15%^{[7](#page-6-6)}. Even in industrialized countries, measles can cause severe complications in unvaccinated adults and in infants too young to receive the vaccine. One of the most worrisome consequences of measles infection is the transient immunosuppression that the virus induces. Afer an infection, the immune system can remain weakened for several months, making the individual susceptible to other infections^{[8](#page-6-7)}. Recent studies have shown that measles can "reset" immune memory, leading to a loss of acquired immunity against other diseases, a phenomenon known as "immune amnesia["6](#page-6-5) .

The introduction of the measles vaccine combined with mumps and rubella (MMR) has dramatically reduced global mortality and morbidity, especially among children⁹. Between 2000 and 2016, there was a 79% reduction in measles-related deaths due to increased vaccination coverage, which saved about 20 million lives¹⁰. However, in recent years, measles has experienced a resurgence in several regions of the world, including Europe, with numerous outbreaks in Italy, France, and Germany¹¹. In 2019, the number of global cases increased by 300% from the previous year, with significant outbreaks in low- and middle-income countries¹². The surge in cases in recent years can be attributed to several factors, including the spread of misleading information regarding the

1 Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128, Rome, Italy. ²Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy. ³Department of Statistical Sciences, Sapienza University of Rome, 00185, Rome, Italy. [⊠]e-mail: [chiara.romano@unicampus.it;](mailto:chiara.romano@unicampus.it) f.branda@unicampus.it

safety of vaccines, which has led to a decline in confidence in vaccination in some communities¹³. In addition, socioeconomic inequalities within and between countries have created signifcant disparities in access to vaccination¹⁴, putting vulnerable populations at greater risk of infection. Measles prevention, therefore, continues to depend largely on the implementation of extensive vaccination programs and the ability to maintain high rates of vaccination coverage.

However, to ensure global control of the disease, constant monitoring and open access to measles epidemiological data could be a signifcant step forward for research and prevention. Open data would allow researchers to analyze the spread of the virus in greater depth, for example by mapping gaps in vaccination coverage and identifying areas at high risk of transmission, predicting outbreaks, and improving immunization strategies^{15–17}. Publicly accessible datasets also foster collaboration between health institutions, researchers, and policymakers, enhancing the capacity to respond swifly to future outbreaks. Such collaboration leads to greater transparency in managing outbreaks and enables shared decision-making based on real-time data, which is critical for timely public health responses. Tis cooperative framework strengthens global eforts to contain infectious diseases by integrating diverse expertise and resources into a unified approach¹⁸.

In this context, the paper presents an open-access repository that includes data on (i) observed measles virus cases, annual coverage of frst and second doses of MMR vaccine, and annual population in 32 European countries from 2011 to 2023; and (ii) total number of air passengers between each pair of countries in the years 2019, 2020, and 2022. With a broad temporal and geographic coverage, the repository provides a detailed and continuous overview of measles dynamics in Europe, facilitating monitoring of changes over time and cross-country comparisons. Te integration of data on measles cases, vaccination coverage, and demographic characteristics provides a solid basis for examining how the spread of the virus interacts with vaccination efectiveness and population characteristics. In addition, data on airline passengers allow analysis of how international movements infuence the spread of measles, helping to identify routes at greatest risk and assess the impact of travel and quarantine policies. This is particularly useful for developing prevention and response strategies based on a thorough understanding of global transmission dynamics. Open access to this dataset promotes transparency and collaboration among researchers, health institutions, and policy makers, improving the ability to formulate informed and timely health policies. In sum, the dataset is a valuable tool for epidemiological analysis, health policy planning, and evaluation of the efectiveness of vaccination campaigns, contributing to more efective management of public health emergencies.

The remainder of the paper is organized as follows: the Methods section details the data sources used and the procedures adopted to create the fnal dataset. Next, the Data Records section provides an in-depth presentation of the dataset, explaining the structure and content of the data collected. In the Technical Validation section, assessments are made to ensure the consistency and statistical reliability of the data, highlighting any limitations and how they were addressed. Finally, in the Usage Notes section, the potential of the dataset for future research purposes is discussed, exploring possible practical applications and how it may contribute to the development of new study and prevention strategies.

Methods

Data were collected from 32 European countries, comprising the 27 member states of the European Union: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden. Additionally, Montenegro, Norway, Serbia, Switzerland, and the United Kingdom were included. The dataset spans a 13-year period, from 2011 to 2023, and was assembled using public sources such as Eurostat, the World Health Organization (WHO), and the European Centre for Disease Prevention and Control (ECDC). The first dataset created is called "measles.xlsx" and includes the number of observed measles cases, the annual coverage of the frst and second doses of the MMR vaccine, and the total population of the European countries from 2011 to 2023, each of which is described in detail in the following: (i) number of measles cases observed for the EU/EEA countries were downloaded from The Surveillance Atlas of Infectious Diseases, an ECDC tool that provides monthly measles cases from January 2011 to December 2023 for all countries of interest¹⁹ [\(ECDC_measles_cases\)](https://atlas.ecdc.europa.eu/public/index.aspx). The dataset provided by ECDC is based on data provided by WHO and Ministries of Health from the afected countries. For the fve countries Montenegro, Norway, Serbia, Switzerland, and the United Kingdom the reported number of measles cases were downloaded from the World Health Organization data repository^{[20](#page-6-18)} [\(WHO_measles_cases\)](https://immunizationdata.who.int/global?topic=Provisional-measles-and-rubella-data&location=). The indicator between the two data providers is the same. The data have not been transformed and have no missing information. (ii) Regional data on vaccination coverage come from WHO, specifcally the WHO/UNICEF Joint Estimates of National Vaccination Coverage (WUENIC), updated to June 26, 2023²¹ [\(WHO_MMRcoverage](https://immunizationdata.who.int/global/wiise-detail-page/measles-vaccination-coverage?CODE=EUR&GROUP=Countries&ANTIGEN=MCV1+MCV2&YEAR=)). These data estimate the percentage of children who have received the frst and second doses of the MMR vaccine. Missing data, especially in the second dose of MCV, were lef blank. (iii) Population data were downloaded from Eurostat website and custom-ized to include only the information of interest for the 32 countries from 2011 to 2023²² ([Eurostat_population](https://ec.europa.eu/eurostat/databrowser/view/demo_pjan/default/table?lang=en&category=demo.demo_pop)). Missing data for the United Kingdom population from 2021 to 2023 were completed using the 2022 Revision of World Population Prospects, the twenty-seventh edition of the official United Nations population estimates^{[23](#page-6-21)} ([UnitedNation_pop](https://population.un.org/wpp/)). The three files were ultimately merged using the left_join function from the R package *dplyr*, with the three-letter country codes (ISO 3166-1 alpha-3) and the year variable serving as the key felds for the join. Tis operation maintains all rows of the main dataset, the one with monthly measle's reported cases, and repeats the annual population and vaccination coverage values for each month of the corresponding year.

The creation of the air passenger dataset aims to quantify flows of people between countries, a key element in modeling and monitoring epidemics, as population movement afects the spread of infectious dis-eases. Data on air routes were collected from the Eurostat website^{[24](#page-6-22)} for each country, while data provided by the UK Civil Aviation Authority website^{[25](#page-6-23)} were used for routes between the UK and other countries in 2020^{26} 2020^{26} 2020^{26}

(UKCCA_flights2020) and 2022²⁷ (UKCCA_flights2022). The downloaded files were processed using a custom R function, named "Route_num", which was applied to each country and year to calculate the total number of passengers traveling between countries.

Data Records

The peer-reviewed data presented in this paper corresponds to version $2 (V2)$ of the dataset, which has been deposited on Zenodo²⁸. The final dataset contains 4992 observations, corresponding to the product of 12 months, 13 years, and 32 countries, ranging from 2011 to 2023. The repository is organized into three distinct sections: "EpidemiologicalData", containing the related measles information; "FlightPass", which includes fight trajectory and passenger data used for analysis; and "MathematicalModel", comprising the computational models developed to simulate and predict the progression of the outbreak. The structure of the repository is outlined in Fig. [1.](#page-3-0) Each of these sections consists of three folders: "InputData", which contains the input data; "OutputData", which collects the analysis results; and "RScript", which includes the R scripts used for processing and modeling. A detailed description of the fle structure is provided below.

EpidemiologicalData. The input datasets located in the "InputData" folder consist of the following files: "counts.xlsx" (i.e., data on the number of observed measles cases), "measle_vax_eu.xlsx" (i.e., coverage of the frst and second doses of the MMR vaccine), and "population.xlsx" (i.e., total population across 32 countries from 2011 to 2023), thoroughly described in the Methods section of this paper. The "Rscript" folder contains the script "measle_paper.R", which was used to merge the input datasets. The structure of the resulting dataset, named "measles.xlsx", is summarized in Table [1.](#page-4-0)

FlightPass. The input dataset are Excel files named "XXX.xlsx", where "XXX" is the three-letters country's code (ISO 3166-1 alpha-3). The only exception are the files "Eng_2020.csv" and "Eng_2022.csv" which are the fles collecting the raw data for the United Kingdom in 2020 and 2022. Finally, the datasets "GBR_2020_paper. xlsx" and "GBR_2022_paper.xlsx" are a version of the 2020 and 2022 United Kingdom's routes data that looks like the other countries' files. The file "flights_E.xlsx" is an empty 32×32 matrix used as a starting point to get the files in the folder "OutputData". The folder "Rscript" contains the files "flights_reproducible_2019.R", "flights_reproducible_2020.R" and "fights_reproducible_2022.R" which was used to generate the datasets "fights_2019.xlsx", "fights_2020.xlsx", "fights_2022.xlsx". i.e., air travel data for 2019, 2020, and 2022, respectively, covering the pre-pandemic, pandemic, and post-pandemic periods. Each dataset is organized as a 32×32 matrix (see Fig. [2](#page-5-0)), where the rows and columns represent the countries analyzed. The matrix values indicate the number of air passengers traveling between each country pair, with diagonal entries showing domestic fights within each country. Note that the matrices are asymmetrical, and missing route data are left blank.

MathematicalModel. The "InputData" folder within the "MathematicalModel" section contains the essential fles for running the Held, Höhle, Hofmann (HHH) model, namely "hhh4.R", to reproduce the results presented in this work. The folder contains necessary input data files, such as "flights_2019.xlsx", "flights_2020.xlsx", "fights_2022.xlsx", and "measles.xlsx". In addition, it includes utility fles such as "dataimp_prep.R", which prepares data for modeling and analysis of measles spread and vaccination efectiveness in relation to population changes and international travel, as well as "leave12out_mixedcorrnone.rData" and "leave12out_mixedcorrnone. rData" to speed up model execution. The former stores all the estimated models for each possibile formulation of the HHH model. The latter contains all the one-step-ahead prediction, for each model formulation, used to construct the Root Mean Square Error (RMSE). By using the HHH script, users can not only replicate the outcomes but also delve into the underlying model dynamics, which are based on multi-year fight and epidemiological data. This approach ensures both transparency and rigor in validating the study's findings.

Technical Validation

The data used in this study are affected by the availability and quality of source sources, with some specific issues related to data collection for the United Kingdom (UK) in 2020. In particular, UK air route and population information comes from diferent databases than those used for other countries, which may introduce diferences in collection methodologies or estimation. However, it is important to note that all data sources used for this study are Official Statistics, which adhere to strict standards defined by international regulations and protocols. To further ensure the robustness of the data integration process, we performed manual validation by selecting successive samples of 25 observations from the measles dataset and cross-referencing each with the original data source for consistency and coherence. In the "measles" dataset, there are some missing values for the variable "MCV2", which represents the estimated coverage of the second dose of measles vaccine. These gaps are due to incomplete information from the underlying data sources. Similarly, in the "FlightPass" dataset, the missing values are attributed to the absence of direct air routes between some countries. To validate the integrity of the compiled datasets, we applied the HHH model, a multivariate time series model for infectious disease counts, a description of which is given below.

Held, höhle & hofmann model. The HHH model^{[29](#page-6-27)} is a multivariate count data time series model for routine surveillance data, which does not require the number of susceptibles available. The observed number of measles cases (variable "counts" in "measles" dataset, see Table [1](#page-4-0)) are assumed to follow a negative binomial:

$$
Y_{t,k} \sim NB(\mu_{t,k}, \psi_k), \quad t = 2, ..., T, \quad k = 1, ..., K
$$
 (1)

Fig. 1 Schematic structure of the dataset.

$$
\mu_{t,k} = \nu_{t,k} + \lambda_{t,k} Y_{t-1,k} + \phi_{t,k} \sum_{j \neq k} w_{j,k} Y_{t-1,j}
$$
\n(2)

where, in our case, time *t* goes from January 2011 to December 2023 and *k*=32 represent the analyzed European countries. The measles incidence $μ$ _{t,k} can be decomposed additively into two parts: (i) the epidemic component, $\lambda_{t,k} Y_{t-1,k} + \phi_{t,k} \sum_{j \neq k} W_{j,k} Y_{t-1,j}$, should be able to capture occasional outbreaks whereas (ii) the endemic component, $v_{t,k}$, explains a baseline rate of cases that is persistent with a stable temporal pattern. $v_{t,k}$, $\lambda_{t,k}$ and $\phi_{t,k}$ are

Table 1. Structure of the fle "measles.xlsx" within the folder "EpidemiologicalData".

linear predictors covering, respectively, the endemic component as well as the within- and between-unit autoregressive behaviour:

$$
log(\nu_{t,k}) = \alpha^{(\nu)} + b_k^{(\nu)} + c_t^{(\nu)} + \text{offset}_{t,k} + z_{t,k}^{(\nu)'}\beta^{(\nu)}
$$
(3)

$$
log(\lambda_{t,k}) = \alpha^{(\lambda)} + b_k^{(\lambda)} + z_{t,k}^{(\lambda)'} \beta^{(\lambda)}
$$
\n(4)

$$
log(\phi_{t,k}) = \alpha^{(\phi)} + b_k^{(\phi)}
$$
\n(5)

where $\alpha^{(\cdot)}$ are component-specific intercept (also called fixed effect), $b_k^{(\cdot)}$ are spatial random effects, $\beta^{(\cdot)}$ the vector of coefficients for covariates $z_{t,k}^{(.)}$ and $c_t^{(\nu)}$ the seasonal effect. In this application, the overdispersion parameter is identical in every unit: $\psi_k = \psi \forall k$. If the units are regions, as in our case, this may be a realistic assumption.

The fitting procedure is implemented in the R package "surveillance"³⁰, with the function "hhh4". This function allows for a variety of combinations of fxed, random, seasonal, and other covariate efects, as each of the three components can be modelled with diferent efects. To address, among more than 500 model scenarios, which is the best model to ft the data, we used the Root Mean Square Error (RMSE) as validation index:

RMSE =
$$
\sqrt{\frac{1}{12} \sum_{t=1}^{12} (\hat{\mu}_{t,k} - \mu_{t,k})^2}
$$

The estimated values $\hat{\mu}_{t,k}$ are the last year's predicted values (*January2023−December2023*) using all the other times as a validation set. The values μ_t are the reported monthly measles cases in 2023. The function "oneStepAhead", computes successive one-step-ahead predictions for a (random effects) HHH model fitted by hhh4. This function will reft the model for the frst time points until week 144 (December 2022), and use this specifc ft to calculate all subsequent predictions (January 2023 to December 2023).

In the best model, the between-units autoregressive component, Eq. [5](#page-4-1), consists of a fixed effect $\alpha^{(\phi)}$. The neighbourhood weights are the number of fight passengers in 2019, "fights_2019.xlsx", for *t*=2011…2019, the number of fight passengers in 2020, "fights_2020.xlsx", for *t*=2020, 2021 and the number of fight passengers in 2022, "flights_2022.xlsx", for $t = 2022$, 2023. The within-units autoregressive component, Eq. [4,](#page-4-2) consists of a fixed effect $\alpha^{(\lambda)}$, an independent and identical distributed (iid) Gaussian spatial effect $b^{(\lambda)}$ and the covariate "proxi_tot_cov". The covariate "proxi_tot_cov" is a weighted sum of the coverage of both MCV vaccine doses $(0.7*MCV1+0.3*MCV2)$. The endemic component consists of a fixed effect $\alpha^{(v)}$, the covariate "proxi_tot_cov" and a fixed seasonal effects $c_t^{(\nu)}$ of the form with $\omega_s = 2s\pi/12$ due to monthly data. We use the population "Pop_ tot" in each country *k* and year as offset in the epidemic component.

$$
\sum_{s=1}^4 \{\gamma_s \sin(\omega_s t) + \delta_s \cos(\omega_s t)\}\
$$

Figure [3](#page-5-1) presents the observed measles cases alongside the estimated trends from the best-ftting hhh4 model for Austria, Finland, the United Kingdom, and Ireland, spanning the years 2011 to 2023. The model's key components are represented in distinct colors: the between-countries epidemic component is shown in orange, the within-countries epidemic component in blue, and the endemic component in grey. Black dots represent the reported measles cases. Across all four countries, the model demonstrates a strong ft with the observed data, with the epidemic components playing a more signifcant role than the endemic component. Notably, in countries like Finland, which reported fewer measles cases, the between-countries epidemic component becomes

Fig. 3 Observed cases and the hhh4 best model estimated measles trend in Austria, Finland, United Kingdom and Ireland, 2011-2023. The best model's components are displayed in three different colors while the observed counts are black dots.

more infuential in capturing higher spikes in the data, compared to countries with more substantial case counts. Tis model can be further applied to forecast future measles trends in the countries analyzed.

Usage Notes

Tis paper provides a comprehensive epidemiological overview of measles infection rates and MMR vaccination coverage in Europe, all consolidated in a single repository. In addition to epidemiological data, the collection includes information on fight passenger movements, providing valuable context for understanding the spread of infections across national borders. For ease of access and usability, the data and R scripts have been made available in Zenodo^{[28](#page-6-26)} and released under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which allows users to freely share, copy, and redistribute the material in any format, as well as adapt and build upon it for any purpose. The availability of the code, including step-by-step instructions, makes it easy to adapt new data to diferent research needs, facilitating collaborations and the generation of new hypotheses in the feld of public health. Future studies could use this repository to simulate diferent vaccination scenarios, identify regions at highest risk for measles outbreaks, and develop targeted intervention strategies.

Notes. The views and opinions of the authors expressed herein do not necessarily state or reflect those of the ECDC. The accuracy of the authors' statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation afer provision of the data. ECDC shall not be held liable for improper or incorrect use of the data.

Code availability

All data and scripts supporting the results presented in this study have been deposited on Zenodo²⁸ for public access.

Received: 19 September 2024; Accepted: 2 December 2024; Published online: 18 December 2024

References

- 1. Grifn, D. E. & Bellini, W. Measles virus. felds virology. Lippincott-Raven Hashimoto, M., Une, Y. and Mochizuki, M.(2001). Hemagglutinin genotype profles of canine distemper virus from domestic dogs in Japan. *Archives of Virology* **146**, 149–155 (2001). 2. Moss, W. J. Measles. *Te Lancet* **390**, 2490–2502, [https://doi.org/10.1016/S0140-6736\(17\)31463-0](https://doi.org/10.1016/S0140-6736(17)31463-0) (2017).
- 3. Perry, R. T. & Halsey, N. A. Te clinical signifcance of measles: a review. *Te Journal of infectious diseases* **189**, S4–S16 (2004).
- 4. Sato, A. I. & Chatterjee, A. Measles: The road to eradication. In Viral, Parasitic, Bacterial, and Fungal Infections, 167-175 (Elsevier, 2023).
- 5. World Health Organization (WHO). Measles fact sheet. World Health Organization (WHO) (2024).
- 6. Mina, M. J., Metcalf, C. J. E., De Swart, R. L., Osterhaus, A. & Grenfell, B. T. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science* **348**, 694–699 (2015).
- 7. Cherry, J. & Heininger, U. Measles morbidity and mortality in the developed world are greater than the public perceives. *Open Forum Infectious Diseases* **4**, S574–S574 (2017).
- 8. de Vries, R. D., Mesman, A. W., Geijtenbeek, T. B., Duprex, W. P. & de Swart, R. L. Te pathogenesis of measles. *Current opinion in virology* **2**, 248–255 (2012).
- 9. Kuter, B. J., Marshall, G. S., Fergie, J., Schmidt, E. & Pawaskar, M. Prevention of measles, mumps and rubella: 40 years of global experience with mm-rii. *Human Vaccines & Immunotherapeutics* **17**, 5372–5383 (2021).
- 10. Dabbagh, A. Progress toward regional measles elimination—worldwide, 2000–2016. *MMWR. Morbidity and mortality weekly report* **66** (2017).
- 11. Branda, F. *et al*. Global measles surveillance: Trends, challenges, and implications for public health interventions. *Infectious Disease Reports* **16**, 367–379 (2024).
- 12. World Health Organization (WHO). New measles surveillance data for 2019. World Health Organization (WHO) (2019).
- 13. Garett, R. & Young, S. D. Online misinformation and vaccine hesitancy. *Translational behavioral medicine* **11**, 2194–2199 (2021).
- 14. Hajizadeh, M. Socioeconomic inequalities in child vaccination in low/middle-income countries: what accounts for the diferences? *J Epidemiol Community Health* **72**, 719–725 (2018).
- 15. Utazi, C. E. & Tatem, A. J. Precise mapping reveals gaps in global measles vaccination coverage (2021).
- 16. Robert, A., Kucharski, A. J. & Funk, S. Te impact of local vaccine coverage and recent incidence on measles transmission in france between 2009 and 2018. *BMC medicine* **20**, 77 (2022).
- 17. Fu, H. *et al*. Efect of evidence updates on key determinants of measles vaccination impact: a dynamice modelling study in ten highburden countries. *BMC medicine* **19**, 1–15 (2021).
- 18. Tsai, E., Allen, P., Saliba, L. F. & Brownson, R. C. The power of partnerships: state public health department multisector collaborations in major chronic disease programme areas in the united states. *Health Research Policy and Systems* **20**, 80 (2022).
- 19. European Center for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases — measles. [https://atlas.ecdc.](https://atlas.ecdc.europa.eu/public/index.aspx) [europa.eu/public/index.aspx](https://atlas.ecdc.europa.eu/public/index.aspx) (2024).
- 20. World Health Organization (WHO). Measles – number of reported cases. [https://immunizationdata.who.int/global?topic=Provisional](https://immunizationdata.who.int/global?topic=Provisional-measles-and-rubella-data&location=)[measles-and-rubella-data&location=](https://immunizationdata.who.int/global?topic=Provisional-measles-and-rubella-data&location=) (2024).
- 21. World health organization. measles vaccination coverage. who/unicef joint estimates of national immunization coverage (wuenic). [https://immunizationdata.who.int/global/wiise-detail-page/measles-vaccination-coverage?CODE=EUR&GROUP=Countries&A](https://immunizationdata.who.int/global/wiise-detail-page/measles-vaccination-coverage?CODE=EUR&GROUP=Countries&ANTIGEN=MCV1+MCV2&YEAR=) [NTIGEN=MCV1+MCV2&YEAR=](https://immunizationdata.who.int/global/wiise-detail-page/measles-vaccination-coverage?CODE=EUR&GROUP=Countries&ANTIGEN=MCV1+MCV2&YEAR=) (2023).
- 22. Eurostat, the statistical office of the european union. population (national level) (demo_pjan). [https://ec.europa.eu/eurostat/](https://ec.europa.eu/eurostat/databrowser/view/demo_pjan/default/table?lang=en&category=demo.demo_pop) [databrowser/view/demo_pjan/default/table?lang](https://ec.europa.eu/eurostat/databrowser/view/demo_pjan/default/table?lang=en&category=demo.demo_pop)=en&category=demo.demo_pop (2024).
- 23. Population division of the department of economic and social afairs of the united nations secretariat. the 2022 revision of world population prospects. <https://population.un.org/wpp/>(2022).
- 24. Eurostat, the statistical office of the european union. database.<https://ec.europa.eu/eurostat/data/database> (2024).
- 25. Uk civil aviation authority. downloadable data on uk airports. [https://www.caa.co.uk/data-and-analysis/uk-aviation-market/](https://www.caa.co.uk/data-and-analysis/uk-aviation-market/airports/uk-airport-data/) [airports/uk-airport-data/](https://www.caa.co.uk/data-and-analysis/uk-aviation-market/airports/uk-airport-data/) (2024).
- 26. Uk civil aviation authority. international air passenger traffic to and from reporting airports for 2020. table 12.1. [https://www.caa.](https://www.caa.co.uk/Documents/Download/3942/84777cab-434d-4271-8990-5da13e832674/1696) [co.uk/Documents/Download/3942/84777cab-434d-4271-8990-5da13e832674/1696](https://www.caa.co.uk/Documents/Download/3942/84777cab-434d-4271-8990-5da13e832674/1696) (2020).
- 27. Uk civil aviation authority. international air passenger traffic to and from reporting airports for 2022. table 12.1. [https://www.caa.](https://www.caa.co.uk/Documents/Download/9116/47a460b2-0592-4ef7-b24b-aa5e27ccfce4/5647) [co.uk/Documents/Download/9116/47a460b2-0592-4ef7-b24b-aa5e27ccfce4/5647](https://www.caa.co.uk/Documents/Download/9116/47a460b2-0592-4ef7-b24b-aa5e27ccfce4/5647) (2022).
- 28. Branda, C. & Romano, F. Measles. *Zenodo.* <https://doi.org/10.5281/zenodo.13748895> (2024).
- 29. Held, L., Höhle, M. & Hofmann, M. A statistical framework for the analysis of multivariate infectious disease surveillance counts. *Statistical modelling* **5**, 187–199 (2005).
- 30. Höhle, M. An r package for the monitoring of infectious diseases. *Computational Statistics* **22**, 571–582 (2007).

Author contributions

Conceptualisation: C.R., F.B., M.C., G.J.L.; methodology: C.R., G.J.L.; sofware: C.R., G.J.L.; validation: M.C., G.J.L.; formal analysis: C.R.; data curation: C.R., F.B.; writing—original draf preparation: C.R., F.B., F.S., M.C., G.J.L.; writing—revision: C.R., F.B., F.S., M.C., G.J.L; supervision: F.S., M.C., G.J.L. All authors have read and agreed to the published version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to C.R. or F.B.

Reprints and permissions information is available at [www.nature.com/reprints.](http://www.nature.com/reprints)

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

Co O Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit<http://creativecommons.org/licenses/by/4.0/>.

 $© The Author(s) 2024$